Prenatal screening Sample: blood Result: 14 working days

Panorama test

Panorama is a non-invasive prenatal test (NIPT) carried out on the mother’s blood from 9 completed weeks of pregnancy. It assesses the baby’s risk of trisomies 21, 18 and 13, sex chromosome conditions and triploidy, with no risk to the pregnancy.

Test code 7156 Preparing for laboratory tests

Some laboratory tests require specific preparation by the patient, concerning diet before sampling and the time of day at which to come to the laboratory for sampling. The patient can be informed about this by their doctor or by the staff of Sante Laboratorije. Many other tests, however, need no prior preparation, and samples do not have to be collected at a particular time or in relation to meals.

For information, contact us on +381 11 27 62 199 | +381 64 65 87 607 or in writing at office@clinica-sante.rs.

Preparation and sampling

Preparation
Guide to preparing for tests
Sample
Blood
Results available in
14 working days
Where it is done
All laboratories and map

Description

About the test

Panorama is a non-invasive prenatal test (NIPT): it analyses the cell-free DNA in a sample of the mother’s blood, part of which comes from the placenta, that is, from the baby. Unlike amniocentesis and chorionic villus sampling, it carries no risk of miscarriage, because it is done on an ordinary venous blood sample.

Small fragments of cell-free DNA circulate in the mother’s blood, and from this material the test estimates the number of copies of the chromosomes examined. Panorama uses SNP-based technology (single nucleotide polymorphisms, small differences in DNA that are unique to each person), which allows it to tell the mother’s DNA apart from the baby’s; this also allows it to detect triploidy and to determine zygosity in twins. According to the manufacturer’s data, the detection rate for trisomies 21, 18 and 13 in singleton pregnancies is over 99%, so the test helps to avoid invasive procedures when they are not needed.

The test assesses the risk of the following chromosomal conditions in the baby:

  • Trisomy 21 (Down’s syndrome) – the most common chromosomal condition in newborns; it involves learning disability of varying degree, characteristic facial features and frequent heart defects.
  • Trisomy 18 (Edwards’ syndrome) – a severe condition with growth restriction, heart and kidney defects and severe learning disability; life expectancy is very limited.
  • Trisomy 13 (Patau’s syndrome) – severe malformations of the brain, heart and kidneys and cleft lip and palate; most affected babies do not survive their first year.
  • Turner syndrome (45,X) – in girls; short stature, underdeveloped ovaries and infertility, sometimes heart defects; intelligence is usually normal.
  • Klinefelter syndrome (47,XXY) – in boys; taller stature, small testes and infertility, sometimes learning difficulties.
  • Jacobs syndrome (47,XYY) – in boys; often without obvious signs, sometimes taller stature and learning or behavioural difficulties.
  • Triple X syndrome (47,XXX) – in girls; usually without symptoms, sometimes learning and speech difficulties.
  • Triploidy – a whole extra set of chromosomes (69 instead of 46); the baby is as a rule not able to survive, and such a pregnancy can also cause complications for the mother, so early detection matters.

The test can also determine the baby’s sex. In twin pregnancies it assesses the risk of trisomies 21, 18 and 13 and can determine whether the twins are identical or non-identical and the sex of each baby, while the scope of the other assessments depends on the type of twin pregnancy. Knowing the zygosity matters: identical twins may share one placenta, which carries a risk of complications such as twin-to-twin transfusion syndrome (an uneven exchange of blood through the placenta), so such pregnancies need closer monitoring by a fetal medicine specialist. In pregnancies with a donor egg and surrogate pregnancies, the risk of trisomies 21, 18 and 13 is assessed.

When it is recommended

Trisomies 21, 18 and 13 and sex chromosome conditions are the most common chromosomal conditions screened for in pregnancy, and the risk of trisomies rises with the mother’s age. The test is recommended:

  • for pregnant women who want a safe, non-invasive assessment of the risk of the most common chromosomal conditions in the baby;
  • for pregnant women over 35, in whom the risk of these conditions is higher;
  • for women who had a baby with a chromosomal condition in a previous pregnancy;
  • for women with a raised risk on a first-trimester screening test or with an ultrasound finding that needs further assessment, in agreement with their doctor;
  • for women who want to avoid invasive procedures when there is no clear need for them;
  • in natural pregnancies and pregnancies after IVF, including pregnancies with a donor egg and surrogate pregnancies, and in twin pregnancies, with a narrower scope.

The test is not recommended for pregnancies with more than two babies.

Preparation

  • The test is done from 9 completed weeks of pregnancy; the length of the pregnancy should be confirmed by ultrasound.
  • You do not need to fast, and the sample can be given at any time of day.
  • At sampling, a form with details of the pregnancy is completed (length of pregnancy, number of babies, IVF, donor egg or surrogate pregnancy). Bring your ultrasound report and your doctor’s referral, if you have one.
  • If you have had a blood transfusion or an organ or bone marrow transplant, say so before sampling.
  • Before the test, it is advisable to discuss with your gynaecologist or a geneticist what the test can and cannot detect.

Sample

Venous blood from the mother. Cell-free DNA is extracted from the plasma and then analysed in a specialised laboratory.

Interpreting the results

  • Low risk – it is very unlikely that the baby has any of the conditions examined. However, the test does not detect all chromosomal conditions, single-gene disorders or structural defects, so regular ultrasound scans, including the anomaly scans in the first and second trimesters, remain essential.
  • High risk – the test is a screening test, not a diagnosis. The result should be confirmed by an invasive diagnostic procedure (chorionic villus sampling or amniocentesis) and analysis of the baby’s chromosomes (karyotype or chromosomal microarray, arrayCGH). A discussion with a geneticist and a gynaecologist is essential, and decisions about the pregnancy are not made on the basis of this test alone.
  • No result – sometimes no result can be issued; a repeat sample may then be needed.

Your doctor interprets the result together with your symptoms and other findings.

What can affect the result

  • too low a proportion of the baby’s DNA in the mother’s blood (the fetal fraction), for example early in pregnancy, which sometimes means no result can be issued;
  • an incorrectly estimated length of pregnancy, which is why it should be confirmed by ultrasound;
  • a blood transfusion or an organ or bone marrow transplant, as another person’s DNA can affect the result;
  • the placental origin of the baby’s cell-free DNA: the chromosomes of the placenta occasionally differ from those of the baby, which can lead to a false-positive or false-negative result;
  • the type of pregnancy: with twins, a donor egg or a surrogate pregnancy the scope of the test is narrower, and with more than two babies the test is not done.

Related tests

  • fetal anomaly ultrasound scans in the first and second trimesters;
  • Panorama with microdeletions (extended microdeletion panel);
  • chorionic villus sampling or amniocentesis with chromosome analysis (karyotype or chromosomal microarray, arrayCGH) to confirm a raised risk;
  • genetic counselling before and after the test.

How to order tests online?

Add the tests you want to your cart

Choose the tests you need and add them to your cart. Use the site search to find the tests you want more easily.

Pay online or at the laboratory

Payment method:

  • Online – payment uses 3D-Secure, a secure authentication protocol that minimises the risk of fraud.
  • At the laboratory – order your tests online and pay for them when you come to the laboratory.
Have your samples taken at one of our laboratories

After payment, you will receive an email confirming your order, with details of how to prepare for sampling. From then on, you can go to the Sante laboratory you chose when ordering your tests and have your samples taken.

Learn more
Back to top